Quantum BioPharma announces that the first person with multiple sclerosis, MS, has been scanned in a joint study with Massachusetts General Hospital, MGH, scientists to validate a novel positron emission tomography imaging technique to monitor myelin integrity and demyelination in MS. The study is evaluating the PET tracer 18F3F4AP, which was developed by Dr. Pedro Brugarolas, an investigator in the department of Radiology at MGH and Assistant Professor at Harvard Medical School. In previous studies in animals and humans, 18F3F4AP was found to be highly sensitive to demyelinated lesions and have favourable pharmacokinetics, suggesting that it holds promise as a biomarker to monitor changes in demyelination in response to remyelinating or neuroprotective drugs in MS.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Announces Special Dividend Linked to Litigation Proceeds
- Quantum BioPharma announces intention to declare special dividend of CVRs
- Quantum BioPharma Expands Cryptocurrency Investment Portfolio
- Quantum Group purchases more Bitcoin, total investment in digital assets to $5M
- Quantum BioPharma Addresses Misinformation and Financial Agreements